Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma

Haematologica
A E FrankelDavid M Neville

Abstract

Resimmune is a second-generation recombinant immunotoxin composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain antibody fragments reactive with the extracellular domain of CD3ε. We gave intravenous infusions of Resimmune 2.5 - 11.25 μg/kg over 15 minutes to 30 patients (25 with cutaneous T-cell lymphoma, 3 with peripheral T-cell lymphoma, 1 with T-cell large granular lymphocytic leukemia and 1 with T-cell prolymphocytic leukemia) in an inter-patient dose escalation trial. The most common adverse events were fever, chills, hypotension, edema, hypoalbuminemia, hypophosphatemia, and transaminasemia. Among the 25 patients with cutaneous T-cell lymphoma, there were nine responses for a response rate of 36% (95% CI, 18%-57%) including four complete remissions (16%, 95% CI, 5%-36%). The durations of the complete remissions were 72+, 72+, 60+ and 38+ months. There were five partial remissions lasting 3, 3, 3+, 6+ and 14 months. Of 17 patients with a modified skin weighted assessment tool score <50, 17 patients with stage IB/IIB, and 11 patients with both a score <50 and stage IB/IIB, nine (53%), eight (47%), and eight (73%) had responses, respectively. Further studies of Resimmune in patients...Continue Reading

Citations

Nov 27, 2015·American Journal of Hematology·Ryan A Wilcox
Oct 31, 2015·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Marissa MayorPrasad S Adusumilli
Sep 27, 2016·Toxins·Bryan D Fleming, Mitchell Ho
Jan 27, 2016·Critical Reviews in Oncology/hematology·Pier Luigi ZinzaniStefano Pileri
Jul 18, 2019·American Journal of Hematology·Alexandra C HristovRyan A Wilcox
Sep 10, 2019·Expert Opinion on Drug Delivery·Sadia SikderDhananjay Pal
Aug 10, 2017·Expert Opinion on Emerging Drugs·Anna Wolska-WasherTadeusz Robak
Jan 7, 2020·Médecine sciences : M/S·Alicia ContetPeter Lowe
Jan 9, 2018·Leukemia & Lymphoma·Jenna JanigaFarah Abdulla
Dec 24, 2018·Biomedicines·Daniel A Vallera, Robert J Kreitman
Nov 5, 2019·Frontiers in Microbiology·Fatemeh ShafieeAli Jahanian-Najafabadi
Oct 24, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Boris GorovitsArno Kromminga
Mar 25, 2018·Current Oncology Reports·Louise PhotiouH Miles Prince
Feb 15, 2017·Molecular Cancer Therapeutics·Antonella BorgattiDaniel A Vallera
Nov 2, 2019·Journal of Pharmaceutical Sciences·Ji-Sun KimYong-Sung Kim
Nov 17, 2020·Frontiers in Veterinary Science·Eduardo CasasJohn D Lippolis
Jul 24, 2021·American Journal of Hematology·Alexandra C HristovRyan A Wilcox
Aug 14, 2020·ACS Combinatorial Science·Priscilla DoErik C Dreaden
Oct 9, 2021·Stem Cell Research & Therapy·Pouya Safarzadeh KozaniFatemeh Rahbarizadeh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.